Welcome to our dedicated page for Mustang Bio news (Ticker: MBIO), a resource for investors and traders seeking the latest updates and insights on Mustang Bio stock.
Mustang Bio, Inc. (MBIO) is a clinical-stage biopharmaceutical company and a subsidiary of Fortress Biotech, Inc. The company is dedicated to developing and commercializing innovative cancer immunotherapy products that harness the patient's own immune system to target and eradicate cancer cells. Mustang Bio’s approach involves acquiring the rights to cutting-edge technologies through licensing or ownership, funding their research and development, and then either out-licensing or bringing these technologies to market.
Mustang Bio has established strategic partnerships with notable institutions, including the City of Hope National Medical Center (COH) and the Fred Hutchinson Cancer Research Center. These collaborations focus on developing advanced Chimeric Antigen Receptor (CAR) engineered T cell (CAR T) therapies for various cancers.
Among Mustang’s core projects, their key programs are in Phase 1 clinical trials at COH. The MB-101 program is aimed at treating brain cancer, while MB-102 is being developed as a therapeutic agent for acute myeloid leukemia. Additionally, Mustang Bio is concentrating on gene therapies for rare genetic disorders, CAR T therapies for hematologic malignancies, and CAR T therapies for solid tumors.
Recently, Mustang Bio has reported positive interim data from their multicenter Phase 1/2 clinical trial, showcasing a favorable safety and efficacy profile of MB-106 in heavily pre-treated lymphoma patients. For more detailed insights, visit the 65th ASH Annual Meeting and Exposition website.
For further information and ongoing updates about Mustang Bio, you can reach them through the following contacts:
- Jaclyn Jaffe and Nicole McCloskey - Mustang Bio, Inc., (781) 652-4500, ir@mustangbio.com
- Tony Plohoros - Media Relations Contact, 6 Degrees, (908) 591-2839, tplohoros@6degreespr.com
Mustang Bio, a clinical-stage biopharmaceutical company (NASDAQ: MBIO), announced its participation in Chardan’s Virtual 5th Annual Genetic Medicines Conference on October 5, 2021, at 8:00 a.m. ET. Manuel Litchman, M.D., President and CEO, and the leadership team will engage in a fireside chat, with a live webcast available on Mustang's Investor Relations page for 30 days post-event. Mustang focuses on cell and gene therapies targeting hematologic cancers, solid tumors, and rare genetic diseases, and is partnered with leading medical institutions for CAR T therapies and lentiviral gene therapy.
Mustang Bio (NASDAQ: MBIO) announced that Christine Brown, Ph.D. will present updated Phase 1 clinical data on MB-101 (IL13Rα2‐targeted CAR T cells) at two major cancer conferences in October 2021. The first presentation, titled 'CAR T Cells in Primary Brain Tumors', will take place on October 1, 2021, at the First Annual Conference on CNS Clinical Trials. The second presentation, 'Advancing CAR T Cell Therapy for Glioblastoma', is scheduled for October 25, 2021, at the AACR Virtual Special Conference on Brain Cancer. These presentations focus on innovative treatments for brain cancer.
Mustang Bio, Inc. (NASDAQ: MBIO), a biopharmaceutical company focused on cell and gene therapies, announced participation in three virtual investor conferences in September 2021. CEO Manuel Litchman will present at the H.C. Wainwright 23rd Annual Global Investment Conference on September 13, the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit on September 20, and the Cantor Global Healthcare Conference on September 27. Webcasts of the presentations will be available on Mustang's website for about 30 days after the events.
Mustang Bio (NASDAQ: MBIO) reported financial results for Q2 2021, highlighting continued progress in CAR T and gene therapies. Key achievements included a 93% overall response rate and 67% complete response rate for MB-106 in high-risk B-NHL and CLL.
The FDA accepted IND for MB-106, with the first patient enrollment expected soon. Mustang secured an exclusive license for innovative CAR T technology and received PRIME designation from the EMA for MB-107. The company reported cash equivalents of $130.9 million and a reduced net loss of $14.4 million, or $0.16 per share.
Mustang Bio, Inc. (NASDAQ: MBIO) has secured an exclusive license from Mayo Clinic for a cutting-edge technology aimed at advancing CAR T-cell therapy. This novel platform utilizes a two-step method to activate patient T cells in vivo, potentially transforming CAR T administration into an off-the-shelf treatment. Preclinical proof-of-concept is established, with further development set at Mayo Clinic. Mustang plans to file an Investigational New Drug (IND) application for a Phase 1 clinical trial once a lead construct is identified, aiming to enhance patient accessibility and reduce treatment costs.
Mustang Bio (NASDAQ: MBIO) announced that the European Medicines Agency (EMA) has granted Priority Medicines (PRIME) designation to its lentiviral gene therapy MB-107 for treating X-linked severe combined immunodeficiency (XSCID) in infants. This milestone comes as Mustang prepares for a pivotal Phase 2 clinical trial. The therapy has previously received ATMP and Orphan Drug designations from the EMA and FDA. XSCID, a rare genetic disorder, severely compromises the immune system and affects approximately 1 in 225,000 births.
Mustang Bio, Inc. (NASDAQ: MBIO) announced it received a $300,000 tax incentive from the Massachusetts Life Sciences Center (MLSC) to create 20 new jobs in 2021, maintaining this headcount through 2025. The MLSC awarded $19.5 million in total to various life science companies. Mustang's CEO, Manuel Litchman, expressed gratitude for the award, noting its significance amid stiff competition. This funding will aid the company's advancement in gene and CAR T cell therapies, which aim to address hematologic cancers and rare genetic diseases.
Mustang Bio, Inc. (NASDAQ: MBIO) announced that Dr. Manuel Litchman, President and CEO, will present at the Raymond James Human Health Innovation Conference from June 21-23, 2021. Mustang's presentation is scheduled for June 23, 2021, at 8:00 a.m. ET and will be available via webcast for 30 days. The company focuses on cell and gene therapies aimed at treating hematologic cancers, solid tumors, and rare genetic diseases, partnering with leading medical institutions to advance CAR T therapies and gene therapy for genetic disorders.
Mustang Bio (NASDAQ: MBIO) announced encouraging interim data from a Phase 1/2 clinical trial of MB-106, a CD20-targeted CAR T cell therapy for high-risk B-cell non-Hodgkin lymphomas (B-NHL) and chronic lymphocytic leukemia (CLL). The trial showed a 93% overall response rate and a 67% complete response rate among 15 patients. The therapy demonstrated a favorable safety profile, with only 40% of patients experiencing cytokine release syndrome. Mustang aims to initiate a multicenter Phase 1/2 trial later in the year after FDA acceptance of their IND application.
Mustang Bio (NASDAQ: MBIO) will host a webinar on June 15, 2021, at 1:00 p.m. ET to discuss the MB-106 CD20-targeted CAR T cell therapy for high-risk B-cell non-Hodgkin lymphomas and chronic lymphocytic leukemia. Dr. Mazyar Shadman from Fred Hutch will present interim results from the ongoing Phase 1/2 clinical trial. Mustang's management will also share details regarding the initiation of the trial after the FDA accepted its Investigational New Drug application. This presentation is scheduled ahead of the European Hematology Association 2021 Virtual Congress.
FAQ
What is the current stock price of Mustang Bio (MBIO)?
What is the market cap of Mustang Bio (MBIO)?
What is Mustang Bio, Inc.?
What are Mustang Bio's core areas of focus?
Who are Mustang Bio's key partners?
What are Mustang Bio's lead programs?
What recent achievements has Mustang Bio reported?
How does Mustang Bio acquire its technologies?
What is CAR T therapy?
How can I contact Mustang Bio for more information?
Where can I find more detailed updates on Mustang Bio's clinical trials?
Who should media inquiries be directed to?
